Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Head and neck Squamous cell carcinoma (HNSCC) is a complex group of malignancies, posing several challenges to treating physicians. Most patients are diagnosed with locally advanced diseases and treated with strategies integrating surgery, chemotherapy, and radiotherapy. About 50% of these patients will experience a recurrence of the disease. Recurrent/metastatic HNSCC have a poor prognosis with a median survival of about 12 to 15 months despite treatments. Head and neck cancer is the seventh most common cancer worldwide, accounting for 3% of all cancers, with approximately 900,000 new cases and half a million deaths.
·
Human papillomavirus infection is now
recognized as the major causative agent for HNSCC, especially in the oropharynx
(OPSCC), accounting for approximately 60–70% of OPSCC in the United States.
·
HPV(+) HNSCC shows marked differences in
epidemiology and pathophysiology as compared to HPV unrelated or negative (−)
HNSCC.
·
Demographically, HPV(+) OPSCC patients tend to
be younger males with a mean age of diagnosis in the 40–50’s and non-smokers or
oligo-smokers. HPV infection has a 10–30-year latency period between infection
and clinical presentation with HPV(+) OPSCC.
Thelansis’s “Recurrent Head and Neck
Squamous Cell Carcinoma (HNSCC) Market Outlook, Epidemiology,
Competitive Landscape, and Market Forecast Report – 2021 To
2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Recurrent Head and Neck Squamous Cell
Carcinoma (HNSCC) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of
Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) across 8 MM market from
the centre of Excellence/ Public/ Private hospitals participated in the study.
Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm, and Unmet needs.
Recurrent Head and Neck Squamous Cell
Carcinoma (HNSCC) Market
Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment